MX2023001217A - Metodos de tratamiento de linfomas mutantes. - Google Patents

Metodos de tratamiento de linfomas mutantes.

Info

Publication number
MX2023001217A
MX2023001217A MX2023001217A MX2023001217A MX2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A MX 2023001217 A MX2023001217 A MX 2023001217A
Authority
MX
Mexico
Prior art keywords
methods
lymphomas
mutant
treating
treating mutant
Prior art date
Application number
MX2023001217A
Other languages
English (en)
Spanish (es)
Inventor
Duncan Walker
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2023001217A publication Critical patent/MX2023001217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2023001217A 2020-07-30 2021-07-29 Metodos de tratamiento de linfomas mutantes. MX2023001217A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063058891P 2020-07-30 2020-07-30
US202063109854P 2020-11-04 2020-11-04
US202163202242P 2021-06-02 2021-06-02
PCT/US2021/071048 WO2022027058A1 (en) 2020-07-30 2021-07-29 Methods of treating mutant lymphomas

Publications (1)

Publication Number Publication Date
MX2023001217A true MX2023001217A (es) 2023-03-03

Family

ID=80036177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001217A MX2023001217A (es) 2020-07-30 2021-07-29 Metodos de tratamiento de linfomas mutantes.

Country Status (13)

Country Link
US (2) US11857535B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188374A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023536462A (cg-RX-API-DMAC7.html)
KR (1) KR20230044480A (cg-RX-API-DMAC7.html)
CN (1) CN116133692A (cg-RX-API-DMAC7.html)
AU (1) AU2021316053A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001638A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187255A1 (cg-RX-API-DMAC7.html)
IL (1) IL300175A (cg-RX-API-DMAC7.html)
MX (1) MX2023001217A (cg-RX-API-DMAC7.html)
PH (1) PH12023550237A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220653A (cg-RX-API-DMAC7.html)
WO (1) WO2022027058A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
WO2022236339A1 (en) * 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN115572768B (zh) * 2022-11-04 2023-12-19 山东第一医科大学附属省立医院(山东省立医院) 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2024191788A1 (en) * 2023-03-10 2024-09-19 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス, インコーポレイテッド Ido阻害剤
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019371400B2 (en) * 2018-11-02 2024-10-17 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
WO2022236339A1 (en) * 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof

Also Published As

Publication number Publication date
US20220054453A1 (en) 2022-02-24
US20240316004A1 (en) 2024-09-26
EP4188374A4 (en) 2024-08-14
AU2021316053A1 (en) 2023-03-02
EP4188374A1 (en) 2023-06-07
IL300175A (en) 2023-03-01
TW202220653A (zh) 2022-06-01
BR112023001638A2 (pt) 2023-02-23
US11857535B2 (en) 2024-01-02
CN116133692A (zh) 2023-05-16
JP2023536462A (ja) 2023-08-25
WO2022027058A1 (en) 2022-02-03
CA3187255A1 (en) 2022-02-03
KR20230044480A (ko) 2023-04-04
PH12023550237A1 (en) 2024-04-29

Similar Documents

Publication Publication Date Title
PH12023550237A1 (en) Methods of treating mutant lymphomas
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
PH12023500023A1 (en) Cdk2 degraders and uses thereof
MX2023000081A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
JOP20200022A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
JOP20200023A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
WO2022082014A3 (en) Skin targeted immunotolerance
PH12022550130A1 (en) Enzyme inhibitors
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12022550118A1 (en) Enzyme inhibitors
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
ZA202201713B (en) Improved treatment using eyp001
MX2025002519A (es) Derivados de piridazinona como degradadores de kat2 para el tratamiento de trastornos proliferativos
PH12022550078A1 (en) Enzyme inhibitors
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
ZA202307787B (en) Pretomanid amorphous form